• PharmaTutor
    9 August 2018

    The Needle-free Injection Technology Enjoys Tremendous Opportunity

    Injections are a common method of injecting drugs into a patient to prevent or cure diseases. However, it is an invasive mode of drug administration as it causes tissue damage. Moreover, injections can cause the transmission of diseases, especially when needles are repeated or used incorrectly. To get rid of these obstacles, the needle-free injection technology (NFIT) was developed. It has gained enormous popularity in the past few years due to its potential of making the administration of drugs more efficient, safe, less expensive, and convenient.

  • IN NEXT 25 YEARS PHARMACEUTICAL SCIENCES/MEDICAL SCIENCES PHRASE WILL BE OBSOLETE, AS SMART BODY WILL COME IN AND ARTIFICIAL INTELLIGENCE WILL PLAY CRUCIAL ROLE
    2 August 2018
    IN NEXT 25 YEARS PHARMACEUTICAL SCIENCES/MEDICAL SCIENCES PHRASE WILL BE OBSOLETE, AS SMART BODY WILL COME IN AND ARTIFICIAL INTELLIGENCE WILL PLAY CRUCIAL ROLE

    ABOUT AUTHOR
    Dr. Amit Gangwal
    gangwal.amit@gmail.com

    A new set of global guidelines on managing diabetes (that plan to replace those followed nearly for thirty years) has been released by American College of Physicians, organization comprising internal medicine physicians. The same has been published in medical journal Annals of Internal Medicine. It says clinicians should aim to achieve an HbA1c level between 7% and 8% in most patients with type 2 diabetes (against the current 6.5 to 7%). This new figure has caused disagreement within the medical community. Medical practitioners in India opine that this may lead to serious complications in diabetics; so it should be ignored for Indians. There were around 72 million diabetics in India in 2017 (as per International Diabetes Federation). HbA1c is long-term blood sugar target, hemoglobin A1C (HbA1c) and it is an estimation of a person’s average blood sugar level over the past few months1.

  • The US Federal Drug Administration is aiming to cut the time-to-market and the development costs for new drugs. This will help drive growth in the market for biologics, where over 1000 drugs are currently under development, to 9.6% year on year from its recent rate of 5.4%. Unlike small-molecule drugs that are manufactured through organic or inorganic chemical synthesis, biologics are manufactured by living cells. Biologics are more complex, fragile and difficult to manufacture than small molecules. They cost more to bring to market than the $2 billion average to develop a new drug, despite a trend to outsource development to contract research organizations.

    [adsense:336x280:8701650588]

  • BEAUTY BENEFITS OF VITAMIN E: RESCUE FOR HAIR DAMAGE
    2 June 2018
    BEAUTY BENEFITS OF VITAMIN E: RESCUE FOR HAIR DAMAGE

    ABOUT AUTHOR
    P.V. POWAR
    Dr. D. Y. Patil College of Pharmacy,
    Akurdi, Pune.44

    Vitamin E or Alpha-Tocopherol is fat-soluble antioxidant which supports for rebuild and repair aged tissues. Vitamin E exists in eight chemical forms as shown in bellow diagram

  • ADVANCED TECHNOLOGY ON ACCURACY IN DETECTION OF BREAST CANCER
    24 May 2018
    ADVANCED TECHNOLOGY ON ACCURACY IN DETECTION OF BREAST CANCER

    { DOWNLOAD AS PDF }

    ABOUT AUTHORS
    SUJATHA RAMASAMY 1*, SRIKANTA PRIYADARSHAN PATRA 1,PULAK RANJAN BASAK 1,
    1Technology Information, Forecasting and Assessment Council (TIFAC)-DST, New Delhi, India.
    *sujathar23@gmail.com

    ABSTRACT:
    Breast cancer is one of the leading type of cancer in India. Current methods used in detection of cancer like mammography combined with Digital Infrared Imaging can help learn about  earlier stages of cancer with accuracy.The Niramai an Indian startup developed a software with machine learning and artificial intelligence which can detect and sense cancer cells that are 5 times smaller than what has been done presently. The method is non-contact, painless and free of radiation. This method can help detection of cancer in very early stage before showing any suspicious or alarming signs.

  • Growth In The Pharmaceuticals Market
    17 May 2018
    Growth In The Pharmaceuticals Market

    The global pharma market was worth $934.8 billion in 2017 and will reach $1170 billion in 2021, growing at 5.8%, a report from The Business Research Company shows. This is an accelerated pace compared to 5.2% for the years before 2017, but is slower than the other two large healthcare segments, medical equipment and healthcare services. Healthcare as a whole is growing at over 7% year on year.

  • Tech Integrated healthcare showing way forward
    1 May 2018
    Tech Integrated healthcare showing way forward

    With the introduction of Health2.0 in the mid-2000s and the germination of digital healthcare startups, the sector has undergone new milestones in last 5 years. About 90 percent of the startups evaluated in 2015 were working on preventive healthcare and monitoring solutions, revealed an InnAccel’s report.

  • Indian and foreign pharmaceutical associations need amendment in section 146 of Indian patent act 1970 and form 27 for making Indian patenting system more efficient and it will eliminate vague and unnecessary annual working statement disclosures. Indian patent office has invited responses from stake holders and many pharmaceutical industries and association responded in this regards.

  • Japan continues to be one of the largest pharmaceutical markets in the globe only behind US and China. The country of 12-13 crores population and have greatest potential in pharmaceutical despite difficult demographic landscape. Life expectancy of Japanese population is higher in the world which is almost 80 years for male and 87 years for female. Older people need more medicine and this is the fundamental of pharmaceutical industry in the Japan.

  • FIRST FDA APPROVED DIGITAL MEDICINE – BRIEF NOTE
    10 April 2018
    FIRST FDA APPROVED DIGITAL MEDICINE – BRIEF NOTE

    ABOUT AUTHOR
    Rajesh S Vagh
    PharmaTutor Edu Labs,
    Surat, Gujarat, India
    rajesh@pharmatutor.org

    Last year in November, FDA had approved first DIGITAL MEDICINE, ABILIFY MYCITE which is a drug-device combination product comprised of Otsuka's oral aripiprazole tablets embedded with an Ingestible Event Marker (IEM) sensor. In simple word, it is an aripiprazole tablet with sensor. It is indicated in adults for the treatment of schizophrenia, bipolar I disorder,  acute treatment of manic and mixed episodes as monotherapy and as adjunct to lithium or valproate, maintenance treatment as monotherapy and as adjunct to lithium or valproate and  adjunctive treatment of major depressive disorder.

Subscribe to Pharmapedia